Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts

Avagimyan, Ashot; Fogacci, Federica; Pogosova, Nana; Kakrurskiy, Lev; Kogan, Eugenia; Urazova, Olga; Kobalava, Zhanna; Mikhaleva, Liudmila; Vandysheva, Rositsa; Zarina, Gioeva; Trofimenko, Artem; Navasardyan, Grizelda; Mkrtchyan, Lusine; Galli, Mattia; Jndoyan, Zinaida; Aznauryan, Anait; Saahakyan, Karmen; Agati, Luciano; Shafie, Davood; Cicero, Arrigo; Salvo, Giovanni Di; Sarrafzadegan, Nizal

doi:10.1016/j.cpcardiol.2023.102052

Cited by 11 publications

(4 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to T2D macrovascular complications, T2D has direct effects on the myocardium, such as left ventricular hypertrophy [110,111], a complex myocardial dysfunction referred to as diabetic cardiomyopathy (which results in abnormal diastolic and systolic function) [112,113], heart failure [114][115][116], and also prolonged ventricular repolarization [117].…”

Section: The Relationship Between Type 2 Diabetes Obesity and Hfpefmentioning

confidence: 99%

New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review

Jalil,

Gabrielli,

Ocaranza

et al. 2024

IJMS

View full text Add to dashboard Cite

This review examines the impact of obesity on the pathophysiology of heart failure with preserved ejection fraction (HFpEF) and focuses on novel mechanisms for HFpEF prevention using a glucagon-like peptide-1 receptor agonism (GLP-1 RA). Obesity can lead to HFpEF through various mechanisms, including low-grade systemic inflammation, adipocyte dysfunction, accumulation of visceral adipose tissue, and increased pericardial/epicardial adipose tissue (contributing to an increase in myocardial fat content and interstitial fibrosis). Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from the enteroendocrine L-cells in the gut. GLP-1 reduces blood glucose levels by stimulating insulin synthesis, suppressing islet α-cell function, and promoting the proliferation and differentiation of β-cells. GLP-1 regulates gastric emptying and appetite, and GLP-1 RA is currently indicated for treating type 2 diabetes (T2D), obesity, and metabolic syndrome (MS). Recent evidence indicates that GLP-1 RA may play a significant role in preventing HFpEF in patients with obesity, MS, or obese T2D. This effect may be due to activating cardioprotective mechanisms (the endogenous counter-regulatory renin angiotensin system and the AMPK/mTOR pathway) and by inhibiting deleterious remodeling mechanisms (the PKA/RhoA/ROCK pathway, aldosterone levels, and microinflammation). However, there is still a need for further research to validate the impact of these mechanisms on humans.

show abstract

Section: The Relationship Between Type 2 Diabetes Obesity and Hfpefmentioning

confidence: 99%

New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review

Jalil,

Gabrielli,

Ocaranza

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…When a macrophage cell dies due to neutrophil extracellular trap (NETosis) activation, chromatin is released into the extracellular environment to trap and eliminate microorganisms. One of the direct links between diabetes and atherosclerosis that can be demonstrated in the inflammatory pathways is NETosis. , Clinical studies have shown that the link between inflammation, diabetes, and atherosclerosis increases the risk of CVD. , Therefore, it is essential to look into the anti-inflammatory characteristics of the molecules in relation to CVD. 1 H, 13 C NMR, Fourier transform infrared (FT-IR), and High-resolution mass spectrometry (HRMS) are used to characterize the synthesized structures.…”

Section: Introductionmentioning

confidence: 99%

“…One of the direct links between diabetes and atherosclerosis that can be demonstrated in the inflammatory pathways is NETosis. 30 , 31 Clinical studies have shown that the link between inflammation, diabetes, and atherosclerosis increases the risk of CVD. 32 , 33 Therefore, it is essential to look into the anti-inflammatory characteristics of the molecules in relation to CVD.…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Structural Elucidation, In Silico and In Vitro Studies of New Class of Methylenedioxyphenyl-Based Amide Derivatives as Potential Myeloperoxidase Inhibitors for Cardiovascular Protection

Rajan,

Karthikeyan,

Desikan

2024

ACS Omega

View full text Add to dashboard Cite

Novel methylenedioxyphenyl-based amides, especially N-(4-methoxybenzyl)-6-nitrobenzo-[1,3]-dioxole-5-carboxamide (MDC) and N-(3-acetylphenyl)-6-nitrobenzo-[1,3]-dioxole-5-carboxamide (ADC), potential cardiovascular preventive agents, are successfully synthesized, and their chemical structures are verified by 1 H and 13 C NMR, Fourier transform infrared (FT-IR), high-resolution mass spectrometry (HRMS), and single-crystal Xray diffraction (SC-XRD) analyses. Data obtained from SC-XRD reveal that MDC and ADC are both monoclinic molecules with Z = 2 and 4, respectively. From density functional theory (DFT) calculations, 3.54 and 3.96 eV are the energy gaps of the optimized MDC and ADC structures, respectively. MDC and ADC exhibit an electrophilicity index value of more than 1.5 eV, suggesting that they can act as an electrophile, facilitating bond formation with biomolecules. Hirshfeld surface analysis demonstrates that more than 25% of atomic interactions in both MDC and ADC are from H•••H interactions. Based on pharmacokinetic predictions, MDC and ADC exhibit drug-like properties, and molecular docking simulations revealed favorable interactions with active site pockets. Both MDC and ADC achieved higher docking scores of −7.74 and −7.79 kcal/mol, respectively, with myeloperoxidase (MPO) protein. From docking results, MPO was found to be most favorable followed by dipeptidyl peptidase-4 (DPP-4) and α-glucosidase (α-GD). Antioxidant, anti-inflammatory, and in vitro enzymatic studies of MDC and ADC indicate that MDC is more selective toward MPO and more potent than ADC. The application of MDC to inhibit myeloperoxidase could be ascertained to reduce the cardiovascular risk factor. This can be supported from the results of computational docking (based on hydrogen bonding and docking score), in vitro antioxidant and anti-inflammatory properties, and MPO enzymatic inhibition (based on the percentage of inhibition and IC 50 values).

show abstract

“…mitochondrial dysfunction), endothelial dysfunction, oxidative stress and dysfunctional immune modulation may be the potential pathological bases leading to DbCM in diabetes 3 – 5 . Generally, patients with DbCM exhibit presentations of significant diastolic and systolic impairment and left ventricular hypertrophy 6 . Although therapeutic approaches to treat DbCM, including controlling blood glucose and blood lipid levels 7 , are available, there is currently a lack of drugs that can effectively reverse myocardial injury.…”

Section: Introductionmentioning

confidence: 99%

Potential clinical value of fibrinogen-like protein 1 as a serum biomarker for the identification of diabetic cardiomyopathy

Liu,

Wang,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Diabetic individuals with diabetic cardiomyopathy (DbCM) present with abnormal myocardial structure and function. DbCM cannot be accurately diagnosed due to the lack of suitable diagnostic biomarkers. In this study, 171 eligible participants were divided into a healthy control (HC), type 2 diabetes mellitus (T2DM) patients without DbCM (T2DM), or DbCM group. Serum fibrinogen-like protein 1 (FGL-1) and other biochemical parameters were determined for all participants. Serum FGL-1 levels were significantly higher in patients with DbCM compared with those in the T2DM group and HCs. Serum FGL-1 levels were negatively correlated with left ventricular fractional shortening and left ventricular ejection fraction (LVEF) and positively correlated with left ventricular mass index in patients with DbCM after adjusting for age, sex and body mass index. Interaction of serum FGL-1 and triglyceride levels on LVEF was noted in patients with DbCM. A composite marker including serum FGL-1 and triglycerides could differentiate patients with DbCM from those with T2DM and HCs with an area under the curve of 0.773 and 0.789, respectively. Composite marker levels were negatively correlated with N-terminal B-type natriuretic peptide levels in patients with DbCM. Circulating FGL-1 may therefore be a valuable index reflecting cardiac functions in DbCM and to diagnose DbCM.

show abstract

Diabetic Cardiomyopathy: 2023 Update by the International Multidisciplinary Board of Experts

Cited by 11 publications

References 77 publications

New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review

New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review

Synthesis, Structural Elucidation, In Silico and In Vitro Studies of New Class of Methylenedioxyphenyl-Based Amide Derivatives as Potential Myeloperoxidase Inhibitors for Cardiovascular Protection

Potential clinical value of fibrinogen-like protein 1 as a serum biomarker for the identification of diabetic cardiomyopathy

Contact Info

Product

Resources

About